Compound useful for the treatment of degenerative and inflammatory diseases
US-10328081-B2 · Jun 25, 2019 · US
Compound useful for the treatment of degenerative and inflammatory diseases
US11000528B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11000528-B2 |
| Application number | US-201916407593-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2019 |
| Priority date | Jun 26, 2009 |
| Publication date | May 11, 2021 |
| Grant date | May 11, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of systemic lupus erythematosus, comprising administering an amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment. 2. The method according to claim 1 , comprising administering a further therapeutic agent. 3. The method according to claim 2 , wherein the further therapeutic agent is an agent for the treatment of systemic lupus erythematosus. 4. A method for the treatment of systemic lupus erythematosus, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment. 5. The method according to claim 4 , comprising administering a further therapeutic agent. 6. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of systemic lupus erythematosus. 7. The method according to claim 2 , wherein the compound of Formula I and the further therapeutic agent are administered in combination. 8. The method according to claim 7 , wherein the further therapeutic agent is an agent for the treatment of systemic lupus erythematosus. 9. The method according to claim 5 , wherein the pharmaceutical composition and the further therapeutic agent are administered in combination. 10. The method according to claim 9 , wherein the further therapeutic agent is an agent for the treatment of systemic lupus erythematosus.
Assignees
Inventors
Classifications
Antiasthmatics · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
- A61K31/437Primary
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
linked by a carbon chain containing aromatic rings · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11000528B2 cover?
- The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases a…
- Who is the assignee on this patent?
- Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).